Oncologic Panel Meeting to Focus on Postmarketing Commitments

Drug Industry Daily
KEYWORDS FDA
A A

The FDA will call on its Oncologic Drugs Advisory Committee next month to provide recommendations on how drugmakers can better meet postmarketing commitments for drugs cleared under the accelerated approval process.

To View This Article:

Login

Subscribe To Drug Industry Daily